Oppenheimer analyst Jay Olson maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report) yesterday and set a price target of $9.00. The company’s shares opened today at $0.47.
Olson covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Amgen, and Viking Therapeutics. According to TipRanks, Olson has an average return of 13.9% and a 40.04% success rate on recommended stocks.
In addition to Oppenheimer, Cognition Therapeutics also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued yesterday. However, on October 31, B.Riley Financial maintained a Hold rating on Cognition Therapeutics (NASDAQ: CGTX).
CGTX market cap is currently $19.04M and has a P/E ratio of -0.51.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Cognition Therapeutics (CGTX) Company Description:
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
